Skip NavigationSkip to Content
Loading

ACL Capabilities

The Antibody Characterization Laboratory activities cover the breadth of monoclonal antibody production and characterization.  Antibodies are directed to relevant, cancer-related antigens. More information about the laboratory’s processes can be found at: http://antibodies.cancer.gov/.

NCI’s Office of Cancer Clinical Proteomics Research funds the activity of the ACL, as a resource to the entire cancer research community.

Antibody Characterization Capabilities:

Antibodies characterized using robust developed and SOP-driven procedures 

  • Antibody-specific activity calculated from indirect ELISA titration for binding and antibody concentration assays
  • Western blot using homologous antigen, and antibody
  • PAGE for purity
  • Isotype analysis

Data reviewed, approved, and distributed:

ACL Expertise

  • Design, development, and deployment of FDA approved immunoassays and assay systems
  • cGMP design of reagents and documentation
  • Clinical laboratory operation and management
Characterization through internal collaborations 

  • SPR analysis for binding affinity measurements
  • Immuno MALDI
  • Tissue array (reverse phase) with NCI 60
  • IHC where appropriate

Characterization through external collaborations:

  • Protein arrays by Arizona State University
  • Tissue IHC by the Human Proteome Atlase

Antibodies and cell lines available:

  • Distributed by Developmental Studies Hybridoma Bank, University of Iowa (http://dshb.biology.uiowa.edu) for Research Use Only
  • Commercially available by non-exclusive license from NCI’s Office of Cancer Clinical Proteomics Research (Email cancer.proteomics@mail.nih.gov for more information.)

Page last updated September 26, 2012 @ 4:51 pm